| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we elucidated that cancer associated fibroblasts (CAFs) derived from nodal lesion of malignant lymphoma enhanced glucose metabolism in lymphoma cells leading to those survival through the secretion of pyruvate and exosomes from CAFs. We also elucidated that emetine, approved as an emetic and anti-protozoal drug, demonstrated a therapeutic effect on intractable B-cell lymphoma cells through the inhibition of glucose metabolism. Moreover, we elucidated that exosomes were involved in a susceptibility to anti-pyrimidine drug through the modulation of its transporter. In terms of extranodal lesion of malignant lymphoma, we identified a gene that is specifically expressed in the central nervous system (CNS) lesions and demonstrated that the gene is involved in those formation.
|
